Table 1. Clinicopathological characteristics of patients.
| Variables | Median [IQR] or n [%] |
|---|---|
| Age, years | 73 [70–79] |
| Sex (male/female) | 49 [96]/2 [4] |
| Performance status (0/1) | 49 [96]/2 [4] |
| Smoking status (smoker/non-smoker) | 51 [100]/0 [0] |
| FVC (L) | 3.3 [2.9–3.9] |
| %FVC (%) | 104.6 [93.7–112.9] |
| FEV1 (L) | 2.3 [1.8–2.8] |
| FEV1% (%) | 70.3 [62.9–75.1] |
| CEA (ng/mL) | 2.7 [2.3–4.0] |
| CYFRA (ng/mL) | 1.4 [1.1–2.0] |
| SCC (ng/mL) | 1.6 [1.0–2.3] |
| SUVmax of tumor | 10.1 [6.7–16.5] |
| Tumor diameter on CT (cm) | 2.5 [1.8–3.0] |
| Tumor location (RU/RM/RL/LU/LL) | 15 [29]/2 [4]/19 [37]/9 [18]/6 [12] |
| Clinical stage (IA1/IA2/IA3/IB) | 1 [2]/13 [26]/22 [43]/15 [29] |
| VDT (days) | 263 [91–375] |
| Operative time (minutes) | 154 [140–203] |
| Blood loss (g) | 30 [15–70] |
| Pathological tumor diameter (cm) | 2.2 [1.9–2.6] |
| Pathological T (1/2/3) | 31 [61]/19 [37]/1 [2] |
| Pathological N (0/1/2) | 47 [92]/3 [6]/1 [2] |
| Pathological stage (I/II/III) | 46 [90]/4 [8]/1 [2] |
| Lymphatic invasion (positive/negative) | 2 [4]/49 [96] |
| Vascular invasion (positive/negative) | 11 [22]/40 [78] |
| Pleural invasion (positive/negative) | 11 [22]/40 [78] |
| Adjuvant chemotherapy (yes/no) | 2 [4]/49 [96] |
IQR, interquartile range; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; CEA, carcinoembryonic antigen; CYFRA, cytokeratin 19 fragment; SCC, squamous cell carcinoma antigen; SUVmax, maximum standardized uptake value; CT, computed tomography; RU, right upper-lobe; RM, right middle-lobe; RL, right lower-lobe; LU, left upper-lobe; LL, left lower-lobe; VDT, tumor volume doubling time; T, tumor; N, node.